OBJECTIVE: Depression and alcohol dependence (AD) are common psychiatric disorders that often co-occur. Both disorders are genetically influenced, with heritability estimates in the range of 35-60%. In addition, evidence from twin studies suggests that AD and depression are genetically correlated. Herein, we report results from a genome-wide association study of a comorbid phenotype, in which cases meet the Diagnostic and Statistical Manual of Mental Disorders-IV symptom threshold for major depressive symptomatology and the Diagnostic and Statistical Manual of Mental Disorders-IV criteria for AD. METHODS: Samples (N=467 cases and N=407 controls) were of European-American descent and were genotyped using the Illumina Human 1M BeadChip array. RESULTS: Although no single-nucleotide polymorphism (SNP) meets genome-wide significance criteria, we identified 10 markers with P values less than 1 × 10(-5), seven of which are located in known genes, which have not been previously implicated in either disorder. Genes harboring SNPs yielding P values less than 1 × 10(-5) are functionally enriched for a number of gene ontology categories, notably several related to glutamatergic function. Investigation of expression localization using online resources suggests that these genes are expressed across a variety of tissues, including behaviorally relevant brain regions. Genes that have been previously associated with depression, AD, or other addiction-related phenotypes - such as CDH13, CSMD2, GRID1, and HTR1B - were implicated by nominally significant SNPs. Finally, the degree of overlap of significant SNPs between a comorbid phenotype and an AD-only phenotype is modest. CONCLUSION: These results underscore the complex genomic influences on psychiatric phenotypes and suggest that a comorbid phenotype is partially influenced by genetic variants that do not affect AD alone.
OBJECTIVE:Depression and alcohol dependence (AD) are common psychiatric disorders that often co-occur. Both disorders are genetically influenced, with heritability estimates in the range of 35-60%. In addition, evidence from twin studies suggests that AD and depression are genetically correlated. Herein, we report results from a genome-wide association study of a comorbid phenotype, in which cases meet the Diagnostic and Statistical Manual of Mental Disorders-IV symptom threshold for major depressive symptomatology and the Diagnostic and Statistical Manual of Mental Disorders-IV criteria for AD. METHODS: Samples (N=467 cases and N=407 controls) were of European-American descent and were genotyped using the Illumina Human 1M BeadChip array. RESULTS: Although no single-nucleotide polymorphism (SNP) meets genome-wide significance criteria, we identified 10 markers with P values less than 1 × 10(-5), seven of which are located in known genes, which have not been previously implicated in either disorder. Genes harboring SNPs yielding P values less than 1 × 10(-5) are functionally enriched for a number of gene ontology categories, notably several related to glutamatergic function. Investigation of expression localization using online resources suggests that these genes are expressed across a variety of tissues, including behaviorally relevant brain regions. Genes that have been previously associated with depression, AD, or other addiction-related phenotypes - such as CDH13, CSMD2, GRID1, and HTR1B - were implicated by nominally significant SNPs. Finally, the degree of overlap of significant SNPs between a comorbid phenotype and an AD-only phenotype is modest. CONCLUSION: These results underscore the complex genomic influences on psychiatric phenotypes and suggest that a comorbid phenotype is partially influenced by genetic variants that do not affect AD alone.
Authors: Yung-yu Huang; Maria A Oquendo; Jill M Harkavy Friedman; Lawrence L Greenhill; Beth Brodsky; Kevin M Malone; Vadim Khait; J John Mann Journal: Neuropsychopharmacology Date: 2003-01 Impact factor: 7.853
Authors: Jen C Wang; Anthony L Hinrichs; Heather Stock; John Budde; Rebecca Allen; Sarah Bertelsen; Jennifer M Kwon; William Wu; Danielle M Dick; John Rice; Kevin Jones; John I Nurnberger; Jay Tischfield; Bernice Porjesz; Howard J Edenberg; Victor Hesselbrock; Ray Crowe; Mark Schuckit; Henri Begleiter; Theodore Reich; Alison M Goate; Laura J Bierut Journal: Hum Mol Genet Date: 2004-06-30 Impact factor: 6.150
Authors: Danielle M Dick; Arpana Agrawal; Jen C Wang; Anthony Hinrichs; Sarah Bertelsen; Kathleen K Bucholz; Marc Schuckit; John Kramer; John Nurnberger; Jay Tischfield; Howard J Edenberg; Alison Goate; Laura J Bierut Journal: Addiction Date: 2007-07 Impact factor: 6.526
Authors: Antonio L López-Figueroa; Camille S Norton; Manuel O López-Figueroa; Denise Armellini-Dodel; Sharon Burke; Huda Akil; Juan F López; Stanley J Watson Journal: Biol Psychiatry Date: 2004-02-01 Impact factor: 13.382
Authors: Beth Bennett; Colin Larson; Phillip A Richmond; Aaron T Odell; Laura M Saba; Boris Tabakoff; Robin Dowell; Richard A Radcliffe Journal: Alcohol Clin Exp Res Date: 2015-04 Impact factor: 3.455
Authors: Haley L Yarosh; Shashwath A Meda; Harriet de Wit; Amy B Hart; Godfrey D Pearlson Journal: Psychopharmacology (Berl) Date: 2015-04-07 Impact factor: 4.530
Authors: J J Luykx; S C Bakker; E Lentjes; M Neeleman; E Strengman; L Mentink; J DeYoung; S de Jong; J H Sul; E Eskin; K van Eijk; J van Setten; J E Buizer-Voskamp; R M Cantor; A Lu; M van Amerongen; E P A van Dongen; P Keijzers; T Kappen; P Borgdorff; P Bruins; E M Derks; R S Kahn; R A Ophoff Journal: Mol Psychiatry Date: 2013-01-15 Impact factor: 15.992
Authors: Alex S Nord; Matthew J Blow; Catia Attanasio; Jennifer A Akiyama; Amy Holt; Roya Hosseini; Sengthavy Phouanenavong; Ingrid Plajzer-Frick; Malak Shoukry; Veena Afzal; John L R Rubenstein; Edward M Rubin; Len A Pennacchio; Axel Visel Journal: Cell Date: 2013-12-19 Impact factor: 41.582